Niagen Bioscience Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Niagen Bioscience, Inc. (NAGE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income8.55-4.94-16.84-27.13-20.26-32.77-33.32
Depreciation & Amortization1.481.711.881.631.512.370.84
Stock Based Compensation3.664.755.746.206.940.000.00
Change in Working Capital3.224.62-6.01-4.731.080.435.19
Change in Accounts Receivable-1.282.26-3.32-2.58-0.560.000.00
Change in Inventory5.330.15-1.08-1.92-0.150.000.00
Change in Accounts Payable-1.070.55-0.740.98-0.180.000.00
Change in Other Working Capital-3.522.21-0.78-0.170.560.000.00
Other Operating Activities-3.525.735.87-0.177.079.530.14
Net Cash from Operating Activities12.117.12-15.10-24.16-10.60-20.44-20.91
Investing Activities
Capital Expenditures-0.16-0.15-0.33-0.410.020.01-1.32
Sales/Maturities of Investments0.00-0.140.00-0.41-0.02-0.050.00
Other Investing Activities0.02-0.140.00-0.41-0.020.00-0.32
Net Cash from Investing Activities-0.14-0.14-0.33-0.41-0.17-0.25-1.78
Financing Activities
Debt Repayment-0.01-0.09-0.09-0.03-0.32-0.28-0.20
Common Stock Issued5.430.007.7526.744.866.77-0.40
Other Financing Activities-0.05-0.08-0.08-0.11-0.0522.05-0.02
Net Cash from Financing Activities5.37-0.097.6536.098.6516.88-0.09
Summary
Net Change in Cash17.346.88-7.7811.52-2.12-3.80-22.77
Cash at Beginning of Period27.33-28.6728.2216.7018.8122.6245.39
Cash at End of Period44.6620.4420.4428.2216.7041.4322.62
Free Cash Flow11.957.12-15.10-24.57-10.62-20.45-22.36
Supplemental Disclosures
Interest Paid0.000.000.000.000.010.030.04